Literature DB >> 16650945

Identification and immunological characterization of conserved Mycoplasma hyopneumoniae lipoproteins Mhp378 and Mhp651.

Jochen Meens1, Martin Selke, Gerald-F Gerlach.   

Abstract

Mycoplasma hyopneumoniae, the etiological agent of swine enzootic pneumonia, is an important pathogen in the swine industry worldwide. Investigations on pathogenicity mechanisms as well as current serological detection methods and the development of new recombinant subunit vaccines are hampered by the lack of known and well characterized, species-specific M. hyopneumoniae antigens. As a first step to solve these problems membrane and membrane-associated proteins were enriched from M. hyopneumoniae cells by Triton X-114 fractionation and further analyzed by 2D gel electrophoresis and Western blot analyses using convalescent sera. Two previously unknown immunogenic proteins were identified by quadrupole time-of-flight mass spectrometry and database analyses as the conserved putative lipoproteins, Mhp378 and Mhp651. Both proteins were expressed as recombinant GST fusion proteins and reacted with sera from convalescent pigs. Coated as solid-phase antigen, Mhp651 showed a distinct cross-reaction only with Mycoplasma flocculare specific rabbit hyperimmune serum, whereas Mhp378 was only recognized by the positive control serum directed against M. hyopneumoniae, thereby indicating its species specificity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16650945     DOI: 10.1016/j.vetmic.2006.03.011

Source DB:  PubMed          Journal:  Vet Microbiol        ISSN: 0378-1135            Impact factor:   3.293


  9 in total

1.  Identification, bioinformatics analyses, and expression of immunoreactive antigens of Mycoplasma haemofelis.

Authors:  Joanne B Messick; Andrea P Santos
Journal:  Clin Vaccine Immunol       Date:  2011-06-08

2.  Immune responses induced by replication-defective adenovirus expressing the C-terminal portion of the Mycoplasma hyopneumoniae P97 adhesin.

Authors:  F R Okamba; E Moreau; K Cheikh Saad Bouh; C A Gagnon; B Massie; M Arella
Journal:  Clin Vaccine Immunol       Date:  2007-04-04

3.  Mycoplasma hyopneumoniae mhp379 is a Ca2+-dependent, sugar-nonspecific exonuclease exposed on the cell surface.

Authors:  Jonathan A Schmidt; Glenn F Browning; Philip F Markham
Journal:  J Bacteriol       Date:  2007-02-16       Impact factor: 3.490

4.  Identification of lipoprotein MslA as a neoteric virulence factor of Mycoplasma gallisepticum.

Authors:  S M Szczepanek; S Frasca; V L Schumacher; X Liao; M Padula; S P Djordjevic; S J Geary
Journal:  Infect Immun       Date:  2010-06-01       Impact factor: 3.441

5.  Francisella tularensis T-cell antigen identification using humanized HLA-DR4 transgenic mice.

Authors:  Jieh-Juen Yu; Tatareddy Goluguri; M Neal Guentzel; James P Chambers; Ashlesh K Murthy; Karl E Klose; Thomas G Forsthuber; Bernard P Arulanandam
Journal:  Clin Vaccine Immunol       Date:  2009-12-16

6.  Development of ELISA Using Recombinant Proteins for the Diagnosis of Mycoplasma hyopneumoniae Infection.

Authors:  Simone Simionatto; Silvana Beutinger Marchioro; Marcelo Dos Santos Barbosa; Vanessa Galli; Clarice Brink Brum; Sergio Jorge; Odir Antonio Dellagostin
Journal:  Indian J Microbiol       Date:  2021-09-16       Impact factor: 2.461

7.  Identification of immunogenic proteins and generation of antibodies against Salmonella Typhimurium using phage display.

Authors:  Torsten Meyer; Thomas Schirrmann; André Frenzel; Sebastian Miethe; Janin Stratmann-Selke; Gerald F Gerlach; Katrin Strutzberg-Minder; Stefan Dübel; Michael Hust
Journal:  BMC Biotechnol       Date:  2012-06-15       Impact factor: 2.563

Review 8.  Oligopeptide m13 phage display in pathogen research.

Authors:  Jonas Kügler; Jonas Zantow; Torsten Meyer; Michael Hust
Journal:  Viruses       Date:  2013-10-16       Impact factor: 5.048

Review 9.  Targeting the porcine immune system--particulate vaccines in the 21st century.

Authors:  Kenneth C McCullough; Artur Summerfield
Journal:  Dev Comp Immunol       Date:  2008-09-02       Impact factor: 3.636

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.